Sutro Biopharma (STRO) PT Lowered to $34 at Citizens on Q2 Revenue Miss
Tweet Send to a Friend
Citizens analyst Reni Benjamin lowered the price target on Sutro Biopharma (NASDAQ: STRO) to $34.00 (from $41.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
